Search results
15 wrz 2022 · Left ventricular thrombus incidence and behavior studied by serial two-dimensional echocardiography in acute anterior myocardial infarction: left ventricular wall motion, systemic embolism and oral anticoagulation.
- View EPUB
PK u!3Yoa«, mimetypeapplication/epub+zipPK u!3Y...
- Linda S. Williams
Many diseases with specific indications for specific...
- PDF/Epub
PK u!3Yoa«, mimetypeapplication/epub+zipPK u!3Y...
- Trial
Background—The Randomized Evaluation of Long-term...
- Results From the GEIST
Left ventricular (LV) thrombus formation is a well‐known...
- Intraventricular Thrombus Formation and Embolism in Takotsubo Syndrome
Objective: Takotsubo syndrome (TTS) is characterized by...
- Stroke
National Center. 7272 Greenville Ave.Dallas, TX 75231....
- Peripartum Cardiomyopathy
Peripartum cardiomyopathy is a potentially life-threatening...
- View EPUB
23 wrz 2022 · On the basis of limited data, patients with nonischemic cardiomyopathy with LV thrombus should be treated with OAC for at least 3–6 months, with discontinuation if LV ejection fraction improves to >35% (assuming resolution of the LV thrombus) or if major bleeding occurs.
Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies. AHA Guideline and Statements Hub content for Management of Patients at Risk for and with Left Ventricular Thrombus.
14 wrz 2022 · We suggest that, on the basis of limited data, patients with NICM with LV thrombus should be treated with OAC for at least 3–6 mo, with dis-continuation if LVEF improves to >35% (assuming resolution of the LV thrombus) or if major bleeding occurs.
Left ventricular (LV) thrombus is a feared complication of LV dysfunction associated with high rates of systemic embolism, morbidity, and mortality. Traditionally, LV thrombus has been associated with acute myocardial infarction (MI).
When asked what proportion of LVT found on echo would be verified on CMR, 51% stated <50%, 20% 50–75% and 29% >75%. Regarding frequency of cases seen annually, 41% reported seeing <20 cases and 8% >60 cases. For treatment, 66% preferred VKA whilst 30% used a DOAC (Figure 1).
Management of LV thrombus (LVT) is challenging and crucial to prevent the potential development of thromboembolic complications such as stroke. Anticoagulation with warfarin is recommended for the prevention of thromboembolic events, but novel oral anticoagulants (NOAC) have been used in clinical practice without supporting evidence.
